Sunny Pharmtech Inc.
Sunny Pharmtech Inc. engages in the research, development, and sale of new and generic drug in Taiwan, the United States, and internationally. Its products portfolio include lidocaine ointment that can be used as an anesthetic lubricant for intubation, which temporarily relieves pain associated with minor burns, sunburn, skin abrasions, and insect bites; cyanocobalamin injection for use in vitami… Read more
Sunny Pharmtech Inc. - Asset Resilience Ratio
Sunny Pharmtech Inc. (6676) has an Asset Resilience Ratio of 0.24% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Sunny Pharmtech Inc.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Sunny Pharmtech Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$3.59 Million | 0.24% |
| Total Liquid Assets | NT$3.59 Million | 0.24% |
Asset Resilience Insights
- Limited Liquidity: Sunny Pharmtech Inc. maintains only 0.24% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sunny Pharmtech Inc. Industry Peers by Asset Resilience Ratio
Compare Sunny Pharmtech Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Sunny Pharmtech Inc. (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Sunny Pharmtech Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.20% | NT$3.10 Million | NT$1.59 Billion | -0.22pp |
| 2023-12-31 | 0.41% | NT$7.10 Million | NT$1.71 Billion | -2.56pp |
| 2022-12-31 | 2.98% | NT$48.51 Million | NT$1.63 Billion | -0.53pp |
| 2021-12-31 | 3.51% | NT$55.98 Million | NT$1.59 Billion | +3.35pp |
| 2020-12-31 | 0.16% | NT$2.40 Million | NT$1.50 Billion | -2.43pp |
| 2019-12-31 | 2.59% | NT$41.99 Million | NT$1.62 Billion | -- |